Paul R. Kirchgraber - Feb 2, 2022 Form 4 Insider Report for LABORATORY CORP OF AMERICA HOLDINGS (LH)

Role
CEO, Covance Drug Development
Signature
/s/ Sandra van der Vaart, Attorney-in-Fact for Paul R. Kirchgraber
Stock symbol
LH
Transactions as of
Feb 2, 2022
Transactions value $
-$39,338
Form type
4
Date filed
2/4/2022, 08:44 AM
Previous filing
Nov 3, 2021
Next filing
Feb 8, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction LH Common Stock Options Exercise +443 +4.95% 9.4K Feb 2, 2022 Direct F1
transaction LH Common Stock Tax liability -$39.3K -144 -1.53% $273.18 9.25K Feb 2, 2022 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LH Restricted Stock Unit Options Exercise $0 -443 -9.28% $0.00 4.33K Feb 2, 2022 Common Stock 443 Direct F1, F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock.
F2 Stock withholding to satisfy tax withholding obligations.
F3 The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 2, 2022.
F4 This number reflects the aggregate number of Restricted Stock Units held by the reporting person.